Xencor Inc (XNCR) stock
XNCRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 5/30194% above fair value
$34.39−0.11 (-0.32%)
Close on Nov 18, 2026Market cap $2.56BP/E –Yield –
Xencor r&d expenses
Research and development expenses are spending on new products and technology.
Xencor's R&D Expenses for the twelve months ending Jun 30, 2026 was $255.77M, up 11.4% year over year. For fiscal 2025 it was $239.43M, up 5.2% from the year before. Over ten years it grew 21.5% a year on average. The highest annual figure on record is $253.60M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $239.43M | +5.2% |
| FY2024 | Dec 31, 2024 | $227.69M | -10.2% |
| FY2023 | Dec 31, 2023 | $253.60M | +27.1% |
| FY2022 | Dec 31, 2022 | $199.56M | +3.7% |
| FY2021 | Dec 31, 2021 | $192.51M | +13.4% |
| FY2020 | Dec 31, 2020 | $169.80M | +43.2% |
| FY2019 | Dec 31, 2019 | $118.59M | +21.6% |
| FY2018 | Dec 31, 2018 | $97.50M | +35.8% |
| FY2017 | Dec 31, 2017 | $71.77M | +38.4% |
| FY2016 | Dec 31, 2016 | $51.87M | +51.9% |
| FY2015 | Dec 31, 2015 | $34.14M | +84.4% |
| FY2014 | Dec 31, 2014 | $18.52M | +8.9% |
| FY2013 | Dec 31, 2013 | $17.00M | +34.2% |
| FY2012 | Dec 31, 2012 | $12.67M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $71.91M | +16.6% |
| Q1 FY2026 | Mar 31, 2026 | $64.67M | +10.4% |
| Q4 FY2025 | Dec 31, 2025 | $64.82M | +27.0% |
| Q3 FY2025 | Sep 30, 2025 | $54.37M | -6.6% |
| Q2 FY2025 | Jun 30, 2025 | $61.67M | +0.2% |
| Q1 FY2025 | Mar 31, 2025 | $58.58M | +3.0% |
| Q4 FY2024 | Dec 31, 2024 | $51.06M | -19.0% |
| Q3 FY2024 | Sep 30, 2024 | $58.23M | -10.3% |
| Q2 FY2024 | Jun 30, 2024 | $61.53M | +2.4% |
| Q1 FY2024 | Mar 31, 2024 | $56.87M | -13.2% |
| Q4 FY2023 | Dec 31, 2023 | $63.05M | +22.5% |
| Q3 FY2023 | Sep 30, 2023 | $64.94M | +21.9% |
| Q2 FY2023 | Jun 30, 2023 | $60.06M | +27.6% |
| Q1 FY2023 | Mar 31, 2023 | $65.55M | +37.3% |
| Q4 FY2022 | Dec 31, 2022 | $51.45M | +0.9% |
| Q3 FY2022 | Sep 30, 2022 | $53.27M | +5.3% |
| Q2 FY2022 | Jun 30, 2022 | $47.08M | -4.9% |
| Q1 FY2022 | Mar 31, 2022 | $47.76M | +15.3% |
| Q4 FY2021 | Dec 31, 2021 | $50.99M | +6.3% |
| Q3 FY2021 | Sep 30, 2021 | $50.61M | +13.9% |
| Q2 FY2021 | Jun 30, 2021 | $49.50M | +13.9% |
| Q1 FY2021 | Mar 31, 2021 | $41.41M | +22.0% |
| Q4 FY2020 | Dec 31, 2020 | $47.95M | +75.4% |
| Q3 FY2020 | Sep 30, 2020 | $44.45M | +49.3% |
| Q2 FY2020 | Jun 30, 2020 | $43.46M | +30.5% |
| Q1 FY2020 | Mar 31, 2020 | $33.94M | +20.4% |
| Q4 FY2019 | Dec 31, 2019 | $27.34M | +0.8% |
| Q3 FY2019 | Sep 30, 2019 | $29.77M | +42.1% |
| Q2 FY2019 | Jun 30, 2019 | $33.30M | +42.7% |
| Q1 FY2019 | Mar 31, 2019 | $28.18M | +8.0% |
| Q4 FY2018 | Dec 31, 2018 | $27.13M | +33.0% |
| Q3 FY2018 | Sep 30, 2018 | $20.95M | +8.0% |
| Q2 FY2018 | Jun 30, 2018 | $23.33M | +37.9% |
| Q1 FY2018 | Mar 31, 2018 | $26.09M | +73.4% |
| Q4 FY2017 | Dec 31, 2017 | $20.40M | +52.7% |
| Q3 FY2017 | Sep 30, 2017 | $19.41M | +37.9% |
| Q2 FY2017 | Jun 30, 2017 | $16.92M | – |
| Q1 FY2017 | Mar 31, 2017 | $15.05M | – |
| Q4 FY2016 | Dec 31, 2016 | $13.36M | – |
| Q3 FY2016 | Sep 30, 2016 | $14.07M | – |
See a number that looks wrong?